WWW.JNEUROSCI.ORG
-
The Journal of Neuroscience MBF Stereo Investigator
 QUICK SEARCH:   [advanced]


     
-


HOME
  |  
SEARCH  |   ARCHIVE  |   SUBSCRIBE  |   CONTACT  |   HELP

The Journal of Neuroscience, November 1, 2006, 26(44):11437-11441; doi:10.1523/JNEUROSCI.2436-06.2006

This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Submit an eLetter
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via ISI Web of Science (6)
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Buckwalter, M. S.
Right arrow Articles by Wyss-Coray, T.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Buckwalter, M. S.
Right arrow Articles by Wyss-Coray, T.
Right arrowPubmed/NCBI databases
*Substance via MeSH
Medline Plus Health Information
*Alzheimer's Disease

 Previous Article  |  Next Article 

Brief Communications
Increased T Cell Recruitment to the CNS after Amyloid beta1–42 Immunization in Alzheimer's Mice Overproducing Transforming Growth Factor-beta1

Marion S. Buckwalter,1 Bronwen S. Coleman,1 Manuel Buttini,2 Robin Barbour,2 Dale Schenk,2 Dora Games,2 Peter Seubert,2 and Tony Wyss-Coray1,3

1Neurology and Neurological Sciences, Stanford University, Stanford, California 94305, 2Elan Pharmaceuticals, South San Francisco, California 94080, and 3Geriatric Research, Education, and Clinical Center, Veterans Administration Palo Alto Health Care System, Palo Alto, California 94304

Correspondence should be addressed to Tony Wyss-Coray, Geriatric Research, Education, and Clinical Center, Veterans Administration Palo Alto Health Care System, Palo Alto, CA 94304. Email: twc{at}stanford.edu

Immunotherapy targeting the amyloid beta (Abeta) peptide is a novel therapy under investigation for the treatment of Alzheimer's disease (AD). A clinical trial using Abeta1–42 (AN1792) as the immunogen was halted as a result of development of meningoencephalitis in a small number of patients. The cytokine TGF-beta1 is a key modulator of immune responses that is increased in the brain in AD. We show here that local overexpression of TGF-beta1 in the brain increases both meningeal and parenchymal T lymphocyte number. Furthermore, TGF-beta1 overexpression in a mouse model for AD [amyloid precursor protein (APP) mice] leads to development of additional T cell infiltrates when mice were immunized at a young but not old age with AN1792. Notably, only mice overproducing both Abeta (APP mice) and TGF-beta1 experienced a rise in T lymphocyte number after immunization. One-third of infiltrating T cells were CD4 positive. We did not observe significant differences in B lymphocyte numbers in any of the genotypes or treatment groups. These results demonstrate that TGF-beta1 overproduction in the brain can promote T cell infiltration, in particular after Abeta1–42 immunization. Likewise, levels of TGF-beta1 or other immune factors in brains of AD patients may influence the response to Abeta1–42 immunization.

Key words: Abeta peptide; Alzheimer's disease; immunity; immunotherapy; inflammation; lymphocyte; neuropathology; T cell; vaccination


Received June 8, 2006; revised Aug. 28, 2006; accepted Sept. 25, 2006.

Correspondence should be addressed to Tony Wyss-Coray, Geriatric Research, Education, and Clinical Center, Veterans Administration Palo Alto Health Care System, Palo Alto, CA 94304. Email: twc{at}stanford.edu




This article has been cited by other articles:


Home page
J. Immunol.Home page
M. Yamamoto, T. Kiyota, S. M. Walsh, J. Liu, J. Kipnis, and T. Ikezu
Cytokine-Mediated Inhibition of Fibrillar Amyloid-{beta} Peptide Degradation by Human Mononuclear Phagocytes
J. Immunol., September 15, 2008; 181(6): 3877 - 3886.
[Abstract] [Full Text] [PDF]


Home page
FASEB J.Home page
R. Baron, A. Nemirovsky, I. Harpaz, H. Cohen, T. Owens, and A. Monsonego
IFN-{gamma} enhances neurogenesis in wild-type mice and in a mouse model of Alzheimer's disease
FASEB J, August 1, 2008; 22(8): 2843 - 2852.
[Abstract] [Full Text] [PDF]



-

Home  |   Search  |   Archive  |   Subscribe  |   Contact  |   Help

-
Copyright 2008 by Society for Neuroscience ONLINE ISSN: 1529-2401
-